These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 19223878)

  • 81. [Are synthetic hypoglycemic agents dangerous?].
    Dérot M
    Journ Annu Diabetol Hotel Dieu; 1971 May; 12(0):253-5. PubMed ID: 5164714
    [No Abstract]   [Full Text] [Related]  

  • 82. FDA guidance on cardiovascular risk of antidiabetic therapies: One decade later.
    Bailey CJ
    Diabetes Obes Metab; 2019 May; 21(5):1079-1080. PubMed ID: 30762280
    [No Abstract]   [Full Text] [Related]  

  • 83. A quantitative approach to benefit-risk assessment of medicines--part 1: the development of a new model using multi-criteria decision analysis; part 2: the practical application of a new model.
    Mussen F; Salek S; Walker S
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16 Suppl 1():S42-6. PubMed ID: 17546572
    [No Abstract]   [Full Text] [Related]  

  • 84. Special report from R.J. Ozmon.
    Betts R
    MLO Med Lab Obs; 2008 Apr; 40(4):8. PubMed ID: 18488539
    [No Abstract]   [Full Text] [Related]  

  • 85. Get shrunk at your own risk.
    Begley S
    Newsweek; 2007 Jun; 149(25):49. PubMed ID: 17639776
    [No Abstract]   [Full Text] [Related]  

  • 86. New guidance aims to identify people at risk of early death.
    Hairon N
    Nurs Times; 2008 Oct 7-13; 104(40):21-2. PubMed ID: 18947042
    [No Abstract]   [Full Text] [Related]  

  • 87. More diabetes genes.
    Ruder K
    Diabetes Forecast; 2007 Jul; 60(8):34. PubMed ID: 17707995
    [No Abstract]   [Full Text] [Related]  

  • 88. Chinese herb usage among Chinese Australians with type 2 diabetes.
    Wong AK; Lau PM; Prabaharan V; Pirotta M
    Aust Fam Physician; 2008 Oct; 37(10):791. PubMed ID: 19009733
    [No Abstract]   [Full Text] [Related]  

  • 89. Mark McClellan.
    McClellan M
    Nat Rev Drug Discov; 2009 Feb; 8(2):102. PubMed ID: 19180102
    [No Abstract]   [Full Text] [Related]  

  • 90. Author response.
    Casagrande SS
    Am J Prev Med; 2014 Jan; 46(1):e17-8. PubMed ID: 24355680
    [No Abstract]   [Full Text] [Related]  

  • 91. Anticipating REMS.
    Nat Rev Drug Discov; 2008 Dec; 7(12):963. PubMed ID: 19043440
    [No Abstract]   [Full Text] [Related]  

  • 92. Profile. Michael Fernandez.
    Powell K
    Nat Biotechnol; 2006 Oct; 24(10):1188. PubMed ID: 17033645
    [No Abstract]   [Full Text] [Related]  

  • 93. Cochrane Collaboration's stand versus industry funding.
    Lenzer J
    CMAJ; 2004 Jul; 171(2):122. PubMed ID: 15262873
    [No Abstract]   [Full Text] [Related]  

  • 94. Dealing with complexity in clinical diabetes: the value of archimedes.
    Kahn R
    Diabetes Care; 2003 Nov; 26(11):3168-71. PubMed ID: 14578256
    [No Abstract]   [Full Text] [Related]  

  • 95. ARCHIMEDES AND TRIGONOMETRY.
    Miller GA
    Science; 1928 Jun; 67(1744):555. PubMed ID: 17792577
    [No Abstract]   [Full Text] [Related]  

  • 96. Model-based benefit-risk assessment: can Archimedes help?
    Krishna R
    Clin Pharmacol Ther; 2009 Mar; 85(3):239-40. PubMed ID: 19223878
    [TBL] [Abstract][Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 5.